

CORRECTION

Open Access



Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial

Naser Gharebaghi¹, Rahim Nejadrahim¹, Seyed Jalil Mousavi¹, Seyed-Reza Sadat-Ebrahimi^{2*} and Reza Hajizadeh^{3*}

Correction to: BMC Infect Dis (2020) 20:786
<https://doi.org/10.1186/s12879-020-05507-4>

Following publication of the original article [1], the author identified two errors in the Results section of the Abstract and in Table 2.

The sentence currently reads:

“ The in-hospital mortality rate was significantly lower in the IVIg group compared to the control group (6 [20.0%] vs. 14 [48.3%], respectively; $P = 0.022$). “.

The sentence should read:

“ The in-hospital mortality rate was significantly lower in the IVIg group compared to the control group (6 [20.0%] vs. 14 [48.3%], respectively; $P = 0.025$). “.

Furthermore, the correct Table 2 is given below.

The original article [1] has been corrected.

Author details

¹Department of Infectious Diseases, Urmia University of Medical Sciences, Urmia, Iran. ²Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ³Department of Cardiology, Urmia University of Medical Sciences, Urmia, Iran.

The original article can be found online at <https://doi.org/10.1186/s12879-020-05507-4>.

* Correspondence: [Sadatr@tbzmed.ac.ir](mailto:Sadrat@tbzmed.ac.ir); hajizadh.reza@gmail.com

²Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

³Department of Cardiology, Urmia University of Medical Sciences, Urmia, Iran

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 2 The relationship between study variables and mortality of patients with severe COVID-19

	Mortality		Unadjusted OR (95% CI)	P-value	
	No	Yes			
Treatment Group	24 (61.5)	6 (30)	0.27 (0.08, 0.85)	0.025[#]	
Control Group	15 (38.5)	14 (70)	Ref		
Age (years)	54 (44, 60)	60 (53.5, 70)	1.05 (1.01, 1.1)	0.014	
Gender n (%)	Male	27 (70)	14 (70)	0.96 (0.3, 3.12)	0.951
	Female	12 (30)	6 (30)	Ref	
HTN n (%)	8 (23.3)	5 (25)	1.29 (0.36, 4.63)	0.694	
DM n (%)	11 (20)	5 (25)	0.85 (0.25, 2.9)	0.793	
Chronic lung disease n (%)	1 (6.6)	1 (5)	2 (0.12, 33.76)	0.630	
HR/min	95 (90, 100)	95 (89, 108)	1.02 (0.96, 1.08)	0.543	
Systolic BP (mmHg)	120 (120, 130)	120 (110, 130)	0.97 (0.93, 1.01)	0.173	
Diastolic BP (mmHg)	80 (70, 80)	70 (70, 80)	0.95 (0.88, 1.01)	0.120	
RR /min	19 (18, 22)	20 (18, 22)	0.98 (0.93, 1.04)	0.545	
BT C°	37.1 (36.7, 37.7)	37.1 (36.75, 37.65)	1.26 (0.63, 2.52)	0.518	
O₂ saturation (%)	89 (87, 89)	85 (80, 88)	0.84 (0.74, 0.97)	0.015	
WBC (1000/mm³)	5.1 (4.6, 7.4)	7.2 (5.1, 11.2)	1.00 (1.00, 1.00)	0.743	
Hb (g/dl)	13.9 (12.6, 15)	13.5 (12.05, 15.25)	0.95 (0.8, 1.13)	0.566	
Plt (1000/mm³)	210 (135, 247)	172.5 (139.5, 193)	1.00 (1.00, 1.00)	0.090	
LDH (U/L)	520 (400, 687)	761 (560.5, 1021)	1.00 (1.00, 1.00)	0.003	
BUN (mg/dl)	29 (25, 39)	64 (50, 129.5)	1.06 (1.02, 1.09)	0.001	
Creatinine (mg/dl)	1 (1, 1.2)	1.2 (1.1, 1.55)	3.63 (0.95, 13.87)	0.059	
K (mEq/L)	4 (3.7, 4.4)	4.2 (4.1, 4.3)	0.95 (0.8, 1.14)	0.616	
Na (mEq/L)	138 (137, 139)	138 (135, 143.5)	1.04 (0.95, 1.14)	0.344	
ESR	28 (20, 41)	40 (26, 49.5)	1.01 (0.99, 1.03)	0.424	
AST (U/L)	31 (21, 39)	29.5 (15.5, 52.5)	1.00 (0.97, 1.02)	0.735	
ALT (U/L)	34.5 (25, 41)	38.5 (29.5, 48)	1.01 (0.99, 1.02)	0.306	
BS (mg/dl)	119 (105, 174)	126 (109.5, 184)	1.00 (0.99, 1.01)	0.845	
PaO₂ (mmHg)	46 (40, 50)	39.5 (34, 49)	0.92 (0.85, 0.99)	0.035	
PCO₂ (mmHg)	40 (35, 46)	38 (36, 39.5)	0.99 (0.91, 1.08)	0.798	
HCO₃ (mEq/L)	24 (22, 25)	24.5 (19.5, 26.5)	1.00 (0.89, 1.13)	0.946	
pH	7.3 (7.3, 7.4)	7.3 (7.2, 7.4)	0.04 (0, 8.87)	0.243	